Archived article
Please note that tax, investment, pension and ISA rules can change and the information and any views contained in this article may now be inaccurate.
Biotech Growth Trust PLC - London-based investor in global biotechnology companies - Net asset value per share at March 31, end of financial year, falls 34% to 957.8 pence from 1,446.4p a year ago. Nasdaq Biotechnology Index, its benchmark, fell 7.4% during period. Biotech Growth underperformed benchmark. ‘Following the very strong results of the previous year, this has been a difficult year for the company,’ says Chair Andrew Joy.
‘The principal driver has been the very significant divergence in performance affecting all sectors, but particularly those with a technology base, including biotech, between large capitalisation stocks and smaller capitalisation ones. This represents a reversal in the long trend of recent decades,’ he adds.
For financial year 2022, firm records £206.0 million loss on fair value investments versus gains of £221.1 million a year ago. Regarding future outlook, ‘there are a number of potential catalysts that could lead to a recovery in the biotechnology sector this year and into the future,’ Biotech Growth adds.
Current stock price: 821.17 pence, up 1.4% on Wednesday
12-month change: down 39%
Copyright 2022 Alliance News Limited. All Rights Reserved.